Cyrano Therapeutics: Funding, Investors & Team (Oct 2026)
Cyrano Therapeutics is working on a nasal product that aims to help patients with a long-term loss of taste and smell regain their functions. The company's product, known as CYR-001, is using an already approved molecule (Theophylline) for a new purpose and has shown successful results in a small initial study. Out of the 10 patients who participated, 8 experienced significant improvement in their ability to taste and smell within just two weeks, and no negative side effects were reported. Otolaryngologists, who specialize in ear, nose, and throat conditions, will be the primary providers for this treatment, and experts in this field have shown interest in joining the clinical program. Cyrano Therapeutics was established in 2014 and is based in Washington, DC, USA.
Cyrano Therapeutics has raised $21.8M across 2 funding rounds on record, the most recent a Series B of $9.0M announced in Jan 2024.
That round is above the $4.9M median round size for Health Care companies tracked on FundedIQ over the last two years.
Cyrano Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2024.
Cyrano Therapeutics Funding Rounds
Cyrano Therapeutics raised $12.8M in an undisclosed round announced in Dec 2020.
3.1 years later, a Series B of $9.0M was announced in Jan 2024.
Cyrano Therapeutics Founders and Leadership Team
Contact details for the Cyrano Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Cyrano Therapeutics Funding Compared to Other Health Care Startups
Cyrano Therapeutics' latest round of $9.0M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cyrano Therapeutics in Health Care and Washington
Companies Similar to Cyrano Therapeutics
Using technology and the best professionals, Wally, a membership-based dental care service, offers proactive,…
PreciseDx is a unique Cancer Risk Stratification company that offers personalized risk information by…
General Medicine provides a convenient and straightforward way to access top-quality healthcare services with…
Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign…
SedMed provides medical devices that support safer toileting transfers and help prevent falls for individuals…
Aptatek is developing cutting edge technologies for portable disease management devices that will improve…
Flow Medical offers multi-function catheters to aid in the diagnosis and treatment of venous thromboembolic…
Light Wave Dental Management offers management services for high-quality dental offices in Virginia.…
For health care systems and payers focused on improving maternal outcomes and health equity, our product is a…
Tempo Therapeutics creates materials that are designed for regenerative medicine, with a focus on being…
Vibronix was established by Dr. Ji-Xin Cheng and Dr. Pu Wang at Purdue University with the goal of offering…
People with chronic diseases can live their best lives thanks to Vheda Health. We concentrate on three areas…
Cyrano Therapeutics Funding FAQs
What does Cyrano Therapeutics do?
Cyrano Therapeutics is working on a nasal product that aims to help patients with a long-term loss of taste and smell regain their functions. The company's product, known as CYR-001, is using an already approved molecule (Theophylline) for a new purpose and has shown successful results in a small initial study. Out of the 10 patients who participated, 8 experienced significant improvement in their ability to taste and smell within just two weeks, and no negative side effects were reported. Otolaryngologists, who specialize in ear, nose, and throat conditions, will be the primary providers for this treatment, and experts in this field have shown interest in joining the clinical program. Cyrano Therapeutics was established in 2014 and is based in Washington, DC, USA.
How much funding has Cyrano Therapeutics raised?
Cyrano Therapeutics has raised $21.8M across 2 rounds on record. The most recent is a Series B of $9.0M announced in Jan 2024.
When did Cyrano Therapeutics last raise funding?
Cyrano Therapeutics' most recent funding round on record is a Series B of $9.0M, announced in Jan 2024.
Who founded Cyrano Therapeutics?
FundedIQ lists Robert Henkin (Founder) at Cyrano Therapeutics.
Who is the CEO of Cyrano Therapeutics?
Rick Geoffrion is listed as CEO at Cyrano Therapeutics.
Where is Cyrano Therapeutics headquartered?
Cyrano Therapeutics is based in Washington, District of Columbia, United States.
How many employees does Cyrano Therapeutics have?
Cyrano Therapeutics is in the 1-10 employee band.
How does Cyrano Therapeutics' funding compare to other Health Care startups?
Cyrano Therapeutics' latest round of $9.0M is above the $4.9M median round size for Health Care companies on FundedIQ across 3,659 tracked companies over the last two years.
About FundedIQ's Cyrano Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cyrano Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.